Legend Biotech Corp (LEGN) stock price

Legend Biotech Corp (LEGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.67 (+0.51%), Market cap $5.12B, 52-week low–high $16.65 ~ $44.32.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Legend Biotech Corp are updated in real time on BlackAll Trade.

Legend Biotech Corp financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Legend Biotech Corp (LEGN) stock price?

Legend Biotech Corp trades at $17.67 (+0.51%). Real-time quotes and charts are available on BlackAll Trade.

What is the Legend Biotech Corp (LEGN) market cap?

Legend Biotech Corp has a market cap of about $5.12B.

What does Legend Biotech Corp (LEGN) do?

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other ind